MY203898A - Fc variants with enhanced binding to fcrn and prolonged half-life - Google Patents
Fc variants with enhanced binding to fcrn and prolonged half-lifeInfo
- Publication number
- MY203898A MY203898A MYPI2020003848A MYPI2020003848A MY203898A MY 203898 A MY203898 A MY 203898A MY PI2020003848 A MYPI2020003848 A MY PI2020003848A MY PI2020003848 A MYPI2020003848 A MY PI2020003848A MY 203898 A MY203898 A MY 203898A
- Authority
- MY
- Malaysia
- Prior art keywords
- binding polypeptides
- fcrn
- variants
- life
- enhanced binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY203898A true MY203898A (en) | 2024-07-23 |
Family
ID=65520379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020003848A MY203898A (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (https=) |
| EP (1) | EP3743441A1 (https=) |
| JP (3) | JP7399880B2 (https=) |
| KR (2) | KR20250008975A (https=) |
| CN (2) | CN111788221B (https=) |
| AU (2) | AU2019212638B2 (https=) |
| BR (1) | BR112020015006A2 (https=) |
| CA (1) | CA3089602A1 (https=) |
| CO (1) | CO2020010269A2 (https=) |
| IL (2) | IL276286B2 (https=) |
| MX (2) | MX2020007882A (https=) |
| MY (1) | MY203898A (https=) |
| PH (1) | PH12020551134A1 (https=) |
| SG (1) | SG11202006905YA (https=) |
| TW (1) | TW201940512A (https=) |
| WO (1) | WO2019147973A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276286B2 (en) * | 2018-01-26 | 2025-07-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
| WO2021016571A2 (en) * | 2019-07-25 | 2021-01-28 | Genzyme Corporation | Methods of treating antibody-mediated disorders with fcrn antagonists |
| CA3156803A1 (en) | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| CN120590527A (zh) * | 2020-05-11 | 2025-09-05 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物和使用方法 |
| KR20230093483A (ko) * | 2020-10-29 | 2023-06-27 | 포르미콘 아게 | Ace2 융합 단백질 및 이의 용도 |
| EP4347640A1 (en) | 2021-05-27 | 2024-04-10 | Sanofi | Fc variant with enhanced affinity to fc receptors and improved thermal stability |
| AU2022329459A1 (en) | 2021-08-20 | 2024-02-29 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
| WO2023064841A1 (en) * | 2021-10-13 | 2023-04-20 | The Wistar Institute Of Anatomy And Biology | Antibodies for use against sars-cov-2 |
| KR20250017240A (ko) | 2022-05-27 | 2025-02-04 | 사노피 | FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자 |
| CN116162171B (zh) * | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
| WO2024089609A1 (en) | 2022-10-25 | 2024-05-02 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
| EP4630455A1 (en) | 2022-12-05 | 2025-10-15 | Sanofi | Transferrin receptor binding proteins |
| TW202535925A (zh) | 2023-10-25 | 2025-09-16 | 比利時商艾伯霖克斯公司 | 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體 |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
| WO2026022712A1 (en) | 2024-07-23 | 2026-01-29 | Sanofi | Cereblon ligase modulator and bcma nk cell engager combination therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| PL209392B1 (pl) * | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| AU2005285347A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| AU2005304624B2 (en) * | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) * | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2010068722A1 (en) * | 2008-12-12 | 2010-06-17 | Medimmune, Llc | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| DK2516468T3 (en) * | 2009-12-23 | 2016-05-23 | Synimmune Gmbh | ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP6322411B2 (ja) * | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| WO2014177459A2 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| DK3215528T3 (da) * | 2014-11-06 | 2019-10-07 | Hoffmann La Roche | Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder |
| JP6787888B2 (ja) * | 2014-11-10 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｉｌ−１ベータ抗体及び使用方法 |
| HRP20260151T1 (hr) * | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
| IL276286B2 (en) * | 2018-01-26 | 2025-07-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
-
2019
- 2019-01-25 IL IL276286A patent/IL276286B2/en unknown
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en not_active Ceased
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/es unknown
- 2019-01-25 MY MYPI2020003848A patent/MY203898A/en unknown
- 2019-01-25 KR KR1020247043107A patent/KR20250008975A/ko active Pending
- 2019-01-25 KR KR1020207024432A patent/KR102748986B1/ko active Active
- 2019-01-25 IL IL318916A patent/IL318916A/en unknown
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/pt unknown
- 2019-01-25 TW TW108102958A patent/TW201940512A/zh unknown
- 2019-01-25 CN CN201980015900.4A patent/CN111788221B/zh active Active
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/ja active Active
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 CN CN202411307275.XA patent/CN119350481A/zh active Pending
- 2019-01-25 AU AU2019212638A patent/AU2019212638B2/en active Active
-
2020
- 2020-07-24 MX MX2025009543A patent/MX2025009543A/es unknown
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/es unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204826A patent/AU2025204826A1/en active Pending
- 2025-10-24 JP JP2025179195A patent/JP2026021377A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020128177A (ru) | 2022-02-28 |
| TW201940512A (zh) | 2019-10-16 |
| IL276286B1 (en) | 2025-03-01 |
| CA3089602A1 (en) | 2019-08-01 |
| AU2019212638B2 (en) | 2025-04-03 |
| KR102748986B1 (ko) | 2025-01-02 |
| AU2019212638A1 (en) | 2020-09-17 |
| IL318916A (en) | 2025-04-01 |
| EP3743441A1 (en) | 2020-12-02 |
| KR20200115568A (ko) | 2020-10-07 |
| CN119350481A (zh) | 2025-01-24 |
| BR112020015006A2 (pt) | 2020-12-29 |
| CN111788221B (zh) | 2026-02-13 |
| CO2020010269A2 (es) | 2020-12-10 |
| KR20250008975A (ko) | 2025-01-16 |
| MX2025009543A (es) | 2025-09-02 |
| JP7399880B2 (ja) | 2023-12-18 |
| MX2020007882A (es) | 2020-12-03 |
| CN111788221A (zh) | 2020-10-16 |
| WO2019147973A1 (en) | 2019-08-01 |
| PH12020551134A1 (en) | 2021-05-31 |
| AU2025204826A1 (en) | 2025-07-17 |
| US20190263934A1 (en) | 2019-08-29 |
| JP2026021377A (ja) | 2026-02-10 |
| JP2021511830A (ja) | 2021-05-13 |
| JP2024026255A (ja) | 2024-02-28 |
| IL276286B2 (en) | 2025-07-01 |
| NZ767453A (en) | 2025-03-28 |
| SG11202006905YA (en) | 2020-08-28 |
| IL276286A (en) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551134A1 (en) | Fc variants with enhanced binding to fcrn and prolonged half-life | |
| ZA202409972B (en) | Fcrn antagonists and methods of use | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| ZA202109042B (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| EA202092093A1 (ru) | Композиции и способы перепрограммирования tcr с применением слитых белков | |
| PH12018502361B1 (en) | Gdf15 fusion proteins and uses thereof | |
| MX2021010354A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| MX2023007211A (es) | Anticuerpos antimiostatina y metodos de uso. | |
| MX2023001394A (es) | Genes del factor viii optimizados. | |
| SG10201808158UA (en) | Site-specific glycoengineering of targeting moieties | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| WO2020069184A3 (en) | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy | |
| MY189425A (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
| EA202091198A1 (ru) | Полипептиды, содержащие домен d, и их применение | |
| MY202559A (en) | Anti-ctla-4 antibody and use thereof | |
| WO2019034703A3 (en) | MODIFICATION OF LYMPHOCYTES T | |
| PH12021551633A1 (en) | Prostate neoantigens and their uses | |
| EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
| MX381726B (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). | |
| NZ724196A (en) | Uti fusion proteins | |
| NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| EA201792274A1 (ru) | Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения | |
| WO2021016062A8 (en) | Chimeric antigen receptors containing glypican 2 binding domains | |
| MX2019013211A (es) | Proteinas de union al antigeno anti-jagged1. | |
| AU2019343184A8 (en) | Compositions and methods for treating cancer with anti-CD123 immunotherapy |